ODYSSEY COMBO I - ODYSSEY COMBO I

Description:

The current trial sought to study the safety and efficacy of alirocumab, a PCSK9 inhibitor, compared with placebo in patients who were on maximal tolerated doses of a statin, but had low-density lipoprotein cholesterol (LDL-C) levels higher than recommended goals.